Local medical insurance supplement will eventually become history, drug companies and drug agents under pressure!

[industry trends of pharmaceutical network] on December 17, Sichuan Medical Insurance Bureau announced that it would strictly implement the new version of the national medical insurance catalogue from January 1, 2020 All localities shall not make their own catalogues or use flexible methods to add drugs in the catalogues, nor adjust the limited payment scope of drugs in the catalogues At the same time, 275 Western medicines and 71 Chinese patent medicines in the original Sichuan supplementary catalogue were removed from the catalogue This part of the varieties will be digested year by year in accordance with the national regulations and cleared out of the scope of medical insurance In fact, except for Sichuan, Hunan, Anhui, Shandong, Tianjin, Guangdong, Zhejiang and other places have issued notices calling for the gradual abolition of local medical insurance supplements
Among them, Shandong Provincial Medical Insurance Bureau will list 143 Western medicines and 125 Chinese patent medicines in the 2017 version of the province's medical insurance catalogue, a total of 268 drugs that are not in the scope of the new round of national medical insurance catalogue, and it is expected to transfer them out in batches within three years; according to the notice of Hunan Province, there are 404 remaining original provincial supplementary varieties after removing the national key monitoring varieties and the transferred national medical insurance varieties from the original provincial supplementary catalogue Within three years, these 404 varieties were either successfully transferred to health insurance or took the path of zero expense or retail It can be seen that under the influence of the control of medical insurance fees and the dynamic adjustment of medical insurance catalogue, the local medical insurance supplement will eventually become a history, and there will be a large-scale reshuffle in the Chinese clinical drug market within three years In this context, both pharmaceutical companies and pharmaceutical agents are under certain pressure For pharmaceutical enterprises, on the one hand, affected by the key monitoring drug policies and the clearing of the local medical insurance supplement catalogue, the market of Chinese patent medicine and Chinese herbal pieces will face a major reshuffle For those provincial supplement varieties that do not enter the national medical insurance, and those provincial supplement varieties that belong to the key monitoring drugs, especially the varieties of Chinese patent medicines, the sales will be greatly impacted On the other hand, with the gradual standardization of clinical medication, the traditional "sales with gold" model has no way out, and drugs with unclear clinical value will be phased out The industry believes that there is only one way for these pharmaceutical enterprises to give up the original market and find the market again within three years, otherwise they will face survival difficulties At the same time, pharmaceutical representatives related to the above-mentioned pharmaceutical companies will also be affected It can be seen that many pharmaceutical companies have adjusted their sales teams in 2019 due to the impact of volume purchase For example, the organizational structure of Sanofi's sales team in China has been adjusted since the implementation of the national centralized purchase; in addition, pharmaceutical enterprises such as Carlin pharmaceutical and xinlitai have adjusted their sales team in response to market changes, or even directly disbanded their sales team With the gradual abolition of local medical insurance supplement, some medical representatives are also facing the problem of transformation or job transfer According to industry analysis, the number of medical representatives will decrease rapidly in the future In 2016, there were 3 million medical representatives in China (generally accepted in the industry, without Statistics) Since 2018, especially after 4 + 7, the number of medical representatives will decrease rapidly So, is there really no way for medical representatives to go? The industry believes that pharmaceutical representatives can transform from sales to market access and participate in the cost control of the company's bidding At the same time, we can aim at the innovative drug market After all, innovative drug R & D enterprises still need professionals to explore the higher value of drugs from the aspects of clinical validation, combined drug use and evidence-based medicine, which may be a new opportunity for medicine representatives.